Ono Pharmaceutical Co., Ltd. (OPHLY)
USD 4.06
(-2.17%)
USD 4.06
(-2.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 163.1 Billion JPY | 14.89% |
| 2023 | 141.96 Billion JPY | 37.57% |
| 2022 | 103.19 Billion JPY | 4.95% |
| 2021 | 98.33 Billion JPY | 26.89% |
| 2020 | 77.49 Billion JPY | 24.97% |
| 2019 | 62.01 Billion JPY | 2.19% |
| 2018 | 60.68 Billion JPY | -16.05% |
| 2017 | 72.28 Billion JPY | 136.94% |
| 2016 | 30.5 Billion JPY | 106.21% |
| 2015 | 14.79 Billion JPY | -44.01% |
| 2014 | 26.42 Billion JPY | -17.22% |
| 2013 | 31.92 Billion JPY | -15.78% |
| 2012 | 37.9 Billion JPY | 7.68% |
| 2011 | 35.2 Billion JPY | -11.65% |
| 2010 | 39.84 Billion JPY | -8.35% |
| 2009 | 43.47 Billion JPY | -16.86% |
| 2008 | 52.28 Billion JPY | -1.05% |
| 2007 | 52.84 Billion JPY | -7.19% |
| 2006 | 56.93 Billion JPY | -5.17% |
| 2005 | 60.04 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 41.34 Billion JPY | 113.43% |
| 2024 Q2 | 55.68 Billion JPY | 34.68% |
| 2024 Q4 | 18.44 Billion JPY | -61.23% |
| 2024 Q3 | 47.59 Billion JPY | -14.54% |
| 2024 FY | 163.1 Billion JPY | 14.89% |
| 2023 Q4 | 19.37 Billion JPY | -54.22% |
| 2023 Q2 | 42.1 Billion JPY | 10.34% |
| 2023 Q3 | 42.32 Billion JPY | 0.5% |
| 2023 FY | 141.96 Billion JPY | 37.57% |
| 2023 Q1 | 38.16 Billion JPY | 81.48% |
| 2022 Q3 | 23.99 Billion JPY | -15.44% |
| 2022 Q2 | 28.37 Billion JPY | -4.74% |
| 2022 Q1 | 29.79 Billion JPY | 84.57% |
| 2022 FY | 103.19 Billion JPY | 4.95% |
| 2022 Q4 | 21.02 Billion JPY | -12.37% |
| 2021 Q4 | 16.14 Billion JPY | -45.81% |
| 2021 FY | 98.33 Billion JPY | 26.89% |
| 2021 Q1 | 27.04 Billion JPY | 136.27% |
| 2021 Q2 | 25.35 Billion JPY | -6.23% |
| 2021 Q3 | 29.78 Billion JPY | 17.47% |
| 2020 Q3 | 24.16 Billion JPY | 10.37% |
| 2020 Q1 | 19.98 Billion JPY | 102.55% |
| 2020 Q2 | 21.89 Billion JPY | 9.59% |
| 2020 FY | 77.49 Billion JPY | 24.97% |
| 2020 Q4 | 11.44 Billion JPY | -52.64% |
| 2019 Q4 | 9.86 Billion JPY | -41.96% |
| 2019 Q3 | 16.99 Billion JPY | -1.02% |
| 2019 Q2 | 17.17 Billion JPY | -4.5% |
| 2019 Q1 | 17.98 Billion JPY | 111.7% |
| 2019 FY | 62.01 Billion JPY | 2.19% |
| 2018 Q1 | 14.27 Billion JPY | -24.79% |
| 2018 Q4 | 8.49 Billion JPY | -66.57% |
| 2018 FY | 60.68 Billion JPY | -16.05% |
| 2018 Q3 | 25.4 Billion JPY | 103.01% |
| 2018 Q2 | 12.51 Billion JPY | -12.34% |
| 2017 Q3 | 23.16 Billion JPY | 79.71% |
| 2017 Q1 | 17.24 Billion JPY | 110.73% |
| 2017 FY | 72.28 Billion JPY | 136.94% |
| 2017 Q4 | 18.98 Billion JPY | -18.07% |
| 2017 Q2 | 12.89 Billion JPY | -25.24% |
| 2016 FY | 30.5 Billion JPY | 106.21% |
| 2016 Q3 | 7.92 Billion JPY | 190.15% |
| 2016 Q1 | 11.67 Billion JPY | 794.88% |
| 2016 Q2 | 2.73 Billion JPY | -76.61% |
| 2016 Q4 | 8.18 Billion JPY | 3.31% |
| 2015 Q1 | 2.77 Billion JPY | -10.99% |
| 2015 FY | 14.79 Billion JPY | -44.01% |
| 2015 Q4 | -1.68 Billion JPY | -112.49% |
| 2015 Q2 | 249 Million JPY | -91.03% |
| 2015 Q3 | 13.44 Billion JPY | 5300.8% |
| 2014 Q3 | 10.14 Billion JPY | 101.57% |
| 2014 FY | 26.42 Billion JPY | -17.22% |
| 2014 Q4 | 3.12 Billion JPY | -69.25% |
| 2014 Q2 | 5.03 Billion JPY | -38.02% |
| 2014 Q1 | 8.12 Billion JPY | 166.38% |
| 2013 Q4 | 3.04 Billion JPY | -73.17% |
| 2013 Q2 | 5.42 Billion JPY | -55.07% |
| 2013 Q3 | 11.36 Billion JPY | 109.43% |
| 2013 FY | 31.92 Billion JPY | -15.78% |
| 2013 Q1 | 12.07 Billion JPY | 169.26% |
| 2012 FY | 37.9 Billion JPY | 7.68% |
| 2012 Q1 | 12.18 Billion JPY | 53.81% |
| 2012 Q2 | 5.49 Billion JPY | -54.88% |
| 2012 Q3 | 15.74 Billion JPY | 186.39% |
| 2012 Q4 | 4.48 Billion JPY | -71.5% |
| 2011 FY | 35.2 Billion JPY | -11.65% |
| 2011 Q1 | 11.73 Billion JPY | 121.53% |
| 2011 Q4 | 7.92 Billion JPY | -44.15% |
| 2011 Q3 | 14.18 Billion JPY | 943.49% |
| 2011 Q2 | 1.35 Billion JPY | -88.42% |
| 2010 Q1 | 15.82 Billion JPY | 90.19% |
| 2010 FY | 39.84 Billion JPY | -8.35% |
| 2010 Q4 | 5.29 Billion JPY | -56.42% |
| 2010 Q3 | 12.15 Billion JPY | 85.45% |
| 2010 Q2 | 6.55 Billion JPY | -58.57% |
| 2009 Q4 | 8.32 Billion JPY | -42.37% |
| 2009 Q3 | 14.43 Billion JPY | 74.54% |
| 2009 Q2 | 8.27 Billion JPY | 0.0% |
| 2009 FY | 43.47 Billion JPY | -16.86% |
| 2008 FY | 52.28 Billion JPY | -1.05% |
| 2007 FY | 52.84 Billion JPY | -7.19% |
| 2006 FY | 56.93 Billion JPY | -5.17% |
| 2005 FY | 60.04 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | -1890.76% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | -845.963% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | -2224.726% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 410607.903% |
| Novartis AG | 9.76 Billion USD | -1569.598% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 95.501% |